公司概覽
業務類別 Medical Instruments & Supplies
業務概覽 Avantor Inc provides products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company operates through two segments: Laboratory Solutions and Bioscience Production. It offers materials & consumables, equipment & instrumentation, and services & specialty procurement. Product groups include Equipment & Instrumentation, Services & Specialty Procurement, Proprietary Materials & Consumables, and Third-Party Materials & Consumables. Materials & consumables include high-purity chemicals and reagents, lab supplies, customized excipients, single-use assemblies, chromatography products, sample preparation kits, and fluid handling solutions. It operates in the Americas, Europe, and AMEA.
公司地址 100 Matsonford Road, Suite 200, Building One, Radnor Corporate Center, Radnor, PA, USA, 19087
電話號碼 +1 610 386-1700
傳真號碼 +1 610 573-2650
公司網頁 https://www.avantorsciences.com
員工數量 13500
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Mr. R. Brent Jones Executive Vice President and Chief Financial Officer 美元 611.52K 11/02/2026
Ms. Brittany Hankamer Executive Vice President and Chief Human Resources Officer -- 11/02/2026
Mr. Benoit Gourdier Executive Vice President, Bioscience Production 美元 516.06K 11/02/2026
Mr. Corey Walker President, Laboratory Solutions -- 11/02/2026
Mr. Emmanuel Ligner President and Chief Executive Officer -- 11/02/2026
Mr. Steven W. Eck Senior Vice President and Chief Accounting Officer -- 11/02/2026
Mr. James Bramwell Executive Vice President, Sales and Customer Excellence 美元 486.54K 08/01/2025
Ms. Mary Blenn Executive Vice President and Chief Operating Officer -- 11/02/2026
Mr. Claudius Sokenu Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary 美元 543.65K 11/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Joseph R. Massaro Independent Director 11/02/2026
Mr. Gregory L. Summe Chairman of the Board 11/02/2026
Mr. Sanjeev K. Mehra Independent Director 11/02/2026
Dr. Michael Severino, M.D. Independent Director 11/02/2026
Mr. Simon P Dingemans Independent Director 11/02/2026
Mr. Juan Andres Independent Director 11/02/2026
Ms. Mala Murthy Independent Director 11/02/2026
Ms. Dame Louise Makin, D.B.E.,PhD Independent Director 11/02/2026
Ms. Lan Kang Independent Director 11/02/2026
Mr. John Carethers Independent Director 11/02/2026
Mr. Gregory T. Lucier Independent Director 11/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:16)
代號 名稱 佔比% 持有日期
MIDEXtrackers S&P MidCap 400 Scrd & Scrn ETF0.0002%26/02/2026
AVUSAvantis US Equity ETF0.0001%28/02/2026
ONEOStt Strt® SPDR® Russell 1000 Momt FocETF0.0001%27/02/2026
MMTMState Street® SPDR® S&P® 1500MomtTiltETF0.00005%27/02/2026
ACSGAmerican Century Small Cp Gr Insgts ETF<0.000001%19/12/2025
ACWIiShares MSCI ACWI ETF<0.000001%28/02/2026
AIEQAmplify AI Powered Equity ETF<0.000001%02/06/2025
BBUSJPMorgan BetaBuilders US Equity ETF<0.000001%23/06/2025
BDVLiShares Disciplined Vol Eq Act ETF<0.000001%12/09/2025
BKWOBNY Mellon Women's Opportunities ETF<0.000001%22/07/2025
BLCRiShares Large Cap Core Active ETF<0.000001%28/02/2026
BRHYiShares High Yield Active ETF<0.000001%24/07/2025
BXMXNuveen S&P 500 Buy-Write Income<0.000001%31/05/2025
CDEICalvert US Large-Cp Div, Eq AndIncETF<0.000001%23/06/2025
CFAVictoryShares US 500 Volatility Wtd ETF<0.000001%22/09/2025
CFOVictoryShares US 500 Enh Vol Wtd ETF<0.000001%22/09/2025
CLSEConvergence Long/Short Equity ETF<0.000001%26/02/2026
CRTCXtrackers US National Crtcl Techs ETF<0.000001%17/08/2025
DCORDimensional US Core Equity 1 ETF<0.000001%11/11/2025
DFACDimensional US Core Equity 2 ETF<0.000001%11/11/2025
  1    2    3    4   5    6    7    8  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.